和元生物
(688238)
| 流通市值：50.89亿 | | | 总市值：51.01亿 |
| 流通股本：6.47亿 | | | 总股本：6.49亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 121,787,253.4 | 50,540,466.83 | 267,696,887.26 | 180,353,622.06 |
| 营业总成本 | 222,762,303.94 | 105,516,677.95 | 492,112,471.65 | 341,998,749.46 |
| 其他经营收益 | | | | |
| 营业利润 | -101,163,142.68 | -53,240,091.47 | -232,757,426.93 | -159,788,844.3 |
| 利润总额 | -101,184,720.26 | -53,239,889.99 | -233,079,842.65 | -160,131,214.55 |
| 净利润 | -101,559,075.74 | -53,064,353.68 | -234,810,012.67 | -162,017,387.18 |
| 每股收益 | | | | |
| 其他综合收益 | -145,308.44 | -90,380.13 | 2,026,920.04 | 2,085,099.25 |
| 综合收益总额 | -101,704,384.18 | -53,154,733.81 | -232,783,092.63 | -159,932,287.93 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 483,191,022.71 | 473,392,047.95 | 547,155,399.62 | 536,852,077.65 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,517,959,414.68 | 1,524,786,198.41 | 1,544,636,748.3 | 1,580,119,633.92 |
| 资产总计 | 2,001,150,437.39 | 1,998,178,246.36 | 2,091,792,147.92 | 2,116,971,711.57 |
| 流动负债: | | | | |
| 流动负债合计 | 399,174,667.96 | 368,905,663.89 | 443,953,560.71 | 430,580,658.95 |
| 非流动负债: | | | | |
| 非流动负债合计 | 292,409,994.29 | 271,887,182.47 | 239,733,422.95 | 205,120,144.83 |
| 负债合计 | 691,584,662.25 | 640,792,846.36 | 683,686,983.66 | 635,700,803.78 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,308,053,097.06 | 1,355,707,245.64 | 1,408,097,480.63 | 1,481,419,704.38 |
| 股东权益合计 | 1,309,565,775.14 | 1,357,385,400 | 1,408,105,164.26 | 1,481,270,907.79 |
| 负债和股东权益合计 | 2,001,150,437.39 | 1,998,178,246.36 | 2,091,792,147.92 | 2,116,971,711.57 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 144,608,929.21 | 54,380,664.07 | 286,218,578.08 | 192,949,481.13 |
| 经营活动现金流出小计 | 227,525,249.93 | 120,452,896.78 | 388,813,523.04 | 303,530,296.52 |
| 经营活动产生的现金流量净额 | -82,916,320.72 | -66,072,232.71 | -102,594,944.96 | -110,580,815.39 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 80,437,939.09 | 30,017,532.18 | 351,050,379.83 | 260,573,842.54 |
| 投资活动现金流出小计 | 154,086,480.81 | 113,305,989.08 | 461,581,348.39 | 391,247,921.3 |
| 投资活动产生的现金流量净额 | -73,648,541.72 | -83,288,456.9 | -110,530,968.56 | -130,674,078.76 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 186,650,000 | 116,650,000 | 280,000,000 | 234,903,753.27 |
| 筹资活动现金流出小计 | 159,265,845.06 | 120,992,491.76 | 211,196,271.02 | 193,846,989.46 |
| 筹资活动产生的现金流量净额 | 27,384,154.94 | -4,342,491.76 | 68,803,728.98 | 41,056,763.81 |
| 汇率变动对现金及现金等价物的影响 | -109,542.46 | -50,528.32 | -20,263.68 | -66,210.72 |
| 现金及现金等价物净增加额 | -129,290,249.96 | -153,753,709.69 | -144,342,448.22 | -200,264,341.06 |
| 期末现金及现金等价物余额 | 161,261,553.65 | 136,798,093.92 | 290,551,803.61 | 234,629,910.77 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -129,290,249.96 | - | -144,342,448.22 | - |